1,655 research outputs found

    Longitudinal Numbers-Needed-To-Treat (NNT) for Achieving Various Levels of Analgesic Response and Improvement with Etoricoxib, Naproxen, and Placebo in Ankylosing Spondylitis

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Clinical analgesic trials typically report response as group mean results. However, research has shown that few patients are average and most have responses at the extremes. Moreover, group mean results do not convey response levels and thus have limited value in representing the benefit-risk at an individual level. Responder analyses and numbers-needed-to-treat (NNT) are considered more relevant for evaluating treatment response. We evaluated levels of analgesic response and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score improvement and the associated NNTs.</p> <p>Methods</p> <p>This was a post-hoc analysis of a 6-week, randomized, double-blind study (N = 387) comparing etoricoxib 90 mg, etoricoxib 120 mg, naproxen 1000 mg, and placebo in AS. Spine pain and BASDAI were measured on a 100-mm visual analog scale. The number and percentage of patients achieving ≥30% and ≥50% improvement in both BASDAI and spine pain were calculated and used to determine the corresponding NNTs. Patients who discontinued from the study for any reason were assigned zero improvement beyond 7 days of the time of discontinuation.</p> <p>Results</p> <p>For etoricoxib 90 mg, etoricoxib 120 mg and naproxen 1000 mg, the NNTs at 6 weeks compared with placebo were 2.0, 2.0, and 2.7 respectively for BASDAI ≥30% improvement, and 3.2, 2.8, and 4.1 for ≥50% improvement. For spine pain, the NNTs were 1.9, 2.0, and 3.2, respectively, for ≥30% improvement, and 2.7, 2.5, and 3.7 for ≥50% improvement. The differences between etoricoxib and naproxen exceeded the limit of ±0.5 units described as a clinically meaningful difference for pain. Response rates and NNTs were generally similar and stable over 2, 4, and 6 weeks.</p> <p>Conclusions</p> <p>For every 2 patients treated with etoricoxib, 1 achieved a clinically meaningful (≥30%) improvement in spine pain and BASDAI beyond that expected from placebo, whereas the corresponding values were approximately 1 in every 3 patients treated with naproxen. Use of NNTs and responder analyses provide additional, complementary information beyond population mean responses when assessing efficacy compared to placebo and amongst active therapies.</p

    Spectroscopy of formaldehyde in the 30140-30790cm^-1 range

    Full text link
    Room-temperature absorption spectroscopy of formaldehyde has been performed in the 30140-30790cm^-1 range. Using tunable ultraviolet continuous-wave laser light, individual rotational lines are well resolved in the Doppler-broadened spectrum. Making use of genetic algorithms, the main features of the spectrum are reproduced. Spectral data is made available as Supporting Information

    Design and Key Features of the PIAAC Survey of Adults

    Get PDF
    This chapter gives an overview of the most important features of the Programme for the International Assessment of Adult Competencies (PIAAC) survey as it pertains to two main goals. First, only a well-designed survey will lead to accurate and comparable test scores across different countries and languages both within and across assessment cycles. Second, only an understanding of its complex survey design will lead to proper use of the PIAAC data in secondary analyses and meaningful interpretation of results by psychometricians, data analysts, scientists, and policymakers. The chapter begins with a brief introduction to the PIAAC survey followed by an overview of the background questionnaire and the cognitive measures. The cognitive measures are then compared to what was assessed in previous international adult surveys. Key features of the assessment design are discussed followed by a section describing what could be done to improve future PIAAC cycles

    Emerging Pharmacotherapies for Adult Patients with Acute Lymphoblastic Leukemia

    Get PDF
    Acute lymphoblastic leukemia (ALL) treatment regimes are amongst the longest, most intensive and complex used in hematooncology. Despite this, while treatment of pediatric ALL is a success story, we are far from being able to ensure a durable response in adult ALL. This is not due to failure of induction therapy as a complete remission (CR) is achieved in over 90% of patients. However the challenge remains in ensuring a sustained remission. Furthermore in the face of relapsed disease, salvage therapies currently offer a poor chance of a good outcome. This article reviews the novel agents which show the most promise in the treatment of adult ALL

    Degeneracy: a link between evolvability, robustness and complexity in biological systems

    Get PDF
    A full accounting of biological robustness remains elusive; both in terms of the mechanisms by which robustness is achieved and the forces that have caused robustness to grow over evolutionary time. Although its importance to topics such as ecosystem services and resilience is well recognized, the broader relationship between robustness and evolution is only starting to be fully appreciated. A renewed interest in this relationship has been prompted by evidence that mutational robustness can play a positive role in the discovery of adaptive innovations (evolvability) and evidence of an intimate relationship between robustness and complexity in biology. This paper offers a new perspective on the mechanics of evolution and the origins of complexity, robustness, and evolvability. Here we explore the hypothesis that degeneracy, a partial overlap in the functioning of multi-functional components, plays a central role in the evolution and robustness of complex forms. In support of this hypothesis, we present evidence that degeneracy is a fundamental source of robustness, it is intimately tied to multi-scaled complexity, and it establishes conditions that are necessary for system evolvability

    Efecto del SASP de células tumorales sobre monocitos y macrófagos

    Get PDF
    67 p.El cáncer gástrico es un adenocarcinoma que se diferencia según su histología en intestinal que afecta principalmente a hombres y difuso que afecta más a jóvenes, es una patología con elevada incidencia en nuestro país, que comienza como un cuadro de gastritis y termina como cáncer invasivo mortal. Nuestro sistema inmune detecta células tumorales e incluso las puede eliminar, pero existen ocasiones donde se suprime el sistema inmune, ya que la carcinogénesis altera el genoma y mecanismo celulares, por lo que se pierda la capacidad de respuesta antitumoral o su eliminación tumoral respectivamente. La senescencia es la pérdida irreversible de la capacidad proliferativa de células que se mantienen en un estado metabólicamente activo, es inducida por el acortamiento de los telómeros o por respuesta al estrés. Estas células presentan cambios morfológicos, aumento de ciertas proteínas, como la p16INK4a que es usado como marcador de senescencia celular. También producen fenotipo secretor asociado a senescencia (SASP, senescent-associated secretory phenotype), que es un conjunto de factores de señalización solubles o proteínicos y componentes insolubles o no proteínicos; las células que pertenecen a este fenotipo estimulan la eliminación de células envejecidas o bien, mantienen, incluso exacerban el estado senescente. Los macrófagos son células del sistema fagocítico mononuclear (SFM), forman parte de la inmunidad innato. Su polarización ocurre durante la inflamación, esta puede ser hacia M1 (microbicida) o M2 (antiinflamatorio) dependiendo de la cantidad y el tiempo que se expongan a las citocinas y los factores que se activen. El efecto pleiotropico y las características del microambiente tumoral son cruciales para la proliferación de los macrófagos asociados a tumor y su fenotipo en senescencia
    corecore